ArticleAdvances in therapy2017

Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.

Sven Kohler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.